ALNY vs. AMGN: Alnylam Pharmaceuticals vs. Amgen Stock Comparison
How do Alnylam Pharmaceuticals (ALNY) and Amgen (AMGN) stack up? This page sets them side by side across company profile, performance and risk, profitability, growth, financial strength, dividends, and valuation, with selected fundamentals also measured against each stock's industry-group peers.
Company Profile
Alnylam Pharmaceuticals (ALNY) and Amgen (AMGN) are both classified in the Biotechnology sub-industry within the broader Biotechnology industry, placing them in the closest GICS peer bucket.
| Profile Item | ALNY | AMGN |
|---|---|---|
| Name | Alnylam Pharmaceuticals, Inc. | Amgen Inc. Common Stock |
| Country/Region | United States | United States |
| GICS Sector | Health Care | Health Care |
| GICS Industry Group | Pharmaceuticals, Biotechnology & Life Sciences | Pharmaceuticals, Biotechnology & Life Sciences |
| GICS Industry | Biotechnology | Biotechnology |
| GICS Sub-Industry | Biotechnology | Biotechnology |
| Market Capitalization | 20.89 billion USD | 249.05 billion USD |
| Currency | USD | USD |
| Exchange | Nasdaq | Nasdaq |
| Listing Date | June 1, 2004 | June 17, 1983 |
| Security Type | Common Stock | Common Stock |
Price Performance
Cumulative Growth
Trailing Returns
Calendar-Year Returns
Performance Metrics
| Metric | ALNY | AMGN |
|---|---|---|
| Total Return (1Y) | -64.57% | 48.82% |
| Total Return (3Y, Annualized) | -1.58% | 24.31% |
| Total Return (5Y, Annualized) | -3.13% | 20.67% |
Risk Profile
Drawdown History
Return Distribution
Risk Metrics
| Metric | ALNY | AMGN |
|---|---|---|
| Volatility (1Y, Annualized) | 54.08% | 29.12% |
| Beta (5Y) | 0.45 | 0.43 |
| Max Drawdown (5Y) | -68.25% | -24.86% |
| Avg. Volume (3M) | 1.90M | 2.76M |
Risk-Adjusted Performance
Risk-Return Positioning
Risk-Adjusted Metrics
| Metric | ALNY | AMGN |
|---|---|---|
| Sharpe Ratio (1Y) | -1.27 | 1.53 |
| Sortino Ratio (1Y) | -1.45 | 2.36 |
Profitability
ROE (TTM)
Both companies show strong equity returns, but Alnylam Pharmaceuticals (ALNY) at 138.07% is the standout with ROE above its industry range; Amgen (AMGN) at 78.35% also sits in the top quartile.
ALNY
Pharmaceuticals, Biotechnology & Life Sciences industry group
138.07%
- ALNY
- 138.07%
- Max
- 109.18%
- Q3
- 6.23%
- Median
- -26.66%
- Q1
- -64.05%
- Min
- -167.77%
AMGN
Pharmaceuticals, Biotechnology & Life Sciences industry group
78.35%
- Max
- 109.18%
- AMGN
- 78.35%
- Q3
- 6.23%
- Median
- -26.66%
- Q1
- -64.05%
- Min
- -167.77%
Net Margin (TTM)
Both Alnylam Pharmaceuticals (ALNY) at 52.85% and Amgen (AMGN) at 24.14% keep an unusually large share of revenue as bottom-line profit — each net margin clears its industry’s benchmark range.
ALNY
Pharmaceuticals, Biotechnology & Life Sciences industry group
52.85%
- ALNY
- 52.85%
- Max
- 18.05%
- Q3
- 4.78%
- Median
- 0.00%
- Q1
- -4.14%
- Min
- -17.05%
AMGN
Pharmaceuticals, Biotechnology & Life Sciences industry group
24.14%
- AMGN
- 24.14%
- Max
- 18.05%
- Q3
- 4.78%
- Median
- 0.00%
- Q1
- -4.14%
- Min
- -17.05%
Operating Margin (TTM)
Both Alnylam Pharmaceuticals (ALNY) at 23.72% and Amgen (AMGN) at 35.79% convert sales into operating profit at a top-quartile rate, pointing to tighter cost discipline before financing and tax.
ALNY
Pharmaceuticals, Biotechnology & Life Sciences industry group
23.72%
- Max
- 83.12%
- ALNY
- 23.72%
- Q3
- 14.77%
- Median
- 0.00%
- Q1
- -78.82%
- Min
- -207.40%
AMGN
Pharmaceuticals, Biotechnology & Life Sciences industry group
35.79%
- Max
- 83.12%
- AMGN
- 35.79%
- Q3
- 14.77%
- Median
- 0.00%
- Q1
- -78.82%
- Min
- -207.40%
Profitability Metrics
| Metric | ALNY | AMGN |
|---|---|---|
| ROE (TTM) | 138.07% | 78.35% |
| ROA (TTM) | 9.51% | 8.91% |
| Net Margin (TTM) | 52.85% | 24.14% |
| Operating Margin (TTM) | 23.72% | 35.79% |
| Gross Margin (TTM) | 77.28% | 72.47% |
Growth
Revenue Growth
Alnylam Pharmaceuticals (ALNY) at 65.19% sits in the top revenue growth quartile, while Amgen (AMGN) at 9.95% is closer to the peer norm — faster top-line expansion for ALNY.
EPS Growth
Only one side can be read here: Amgen (AMGN) reports EPS growth of 88.23%, ranked against its industry; Alnylam Pharmaceuticals (ALNY) has no EPS growth figure this period.
Growth Metrics
| Metric | ALNY | AMGN |
|---|---|---|
| Revenue Growth (YoY) | 65.19% | 9.95% |
| Revenue Growth (3Y CAGR) | 52.98% | 11.77% |
| EPS Growth (YoY) | -- | 88.23% |
| EPS Growth (3Y CAGR) | -- | 5.52% |
Financial Strength
Current Ratio (MRQ)
Alnylam Pharmaceuticals (ALNY) at 2.48 keeps current ratio within its industry’s typical mid-range, while Amgen (AMGN) at 1.48 runs in the tighter-liquidity quartile — a thinner cushion against current liabilities for AMGN.
ALNY
Pharmaceuticals, Biotechnology & Life Sciences industry group
2.48
- Max
- 25.13
- Q3
- 12.13
- Median
- 5.52
- ALNY
- 2.48
- Q1
- 2.47
- Min
- 0.10
AMGN
Pharmaceuticals, Biotechnology & Life Sciences industry group
1.48
- Max
- 25.13
- Q3
- 12.13
- Median
- 5.52
- Q1
- 2.47
- AMGN
- 1.48
- Min
- 0.10
Debt / Equity (MRQ)
Both balance sheets lean debt-heavy versus peers, but AMGN is more stretched: Alnylam Pharmaceuticals (ALNY) at 0.83 sits in the higher-leverage quartile and Amgen (AMGN) at 3.76 is above its industry benchmark range.
ALNY
Pharmaceuticals, Biotechnology & Life Sciences industry group
0.83
- Max
- 1.42
- ALNY
- 0.83
- Q3
- 0.65
- Median
- 0.15
- Q1
- 0.02
- Min
- 0.00
AMGN
Pharmaceuticals, Biotechnology & Life Sciences industry group
3.76
- AMGN
- 3.76
- Max
- 1.42
- Q3
- 0.65
- Median
- 0.15
- Q1
- 0.02
- Min
- 0.00
Financial Strength Metrics
| Metric | ALNY | AMGN |
|---|---|---|
| Current Ratio (MRQ) | 2.48 | 1.48 |
| Debt / Equity (MRQ) | 0.83 | 3.76 |
| Net Debt / EBITDA | -0.57 | 2.31 |
Dividends
Dividend Yield (TTM)
Alnylam Pharmaceuticals (ALNY) pays no dividend (yield 0.00%) — it may be reinvesting, using buybacks, or simply not returning cash through dividends. Meanwhile Amgen (AMGN) reports a yield of 2.16%, ranking against industry peers normally.
ALNY
Pharmaceuticals, Biotechnology & Life Sciences industry group
0.00%
- ALNY
- 0.00%
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
AMGN
Pharmaceuticals, Biotechnology & Life Sciences industry group
2.16%
- AMGN
- 2.16%
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
Dividend Payout Ratio (TTM)
Alnylam Pharmaceuticals (ALNY) pays no dividend (payout 0.00%) — it may be reinvesting, using buybacks, or simply not returning cash through dividends. Meanwhile Amgen (AMGN) reports a payout of 57.62%, ranking against industry peers normally.
ALNY
Pharmaceuticals, Biotechnology & Life Sciences industry group
0.00%
- ALNY
- 0.00%
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
AMGN
Pharmaceuticals, Biotechnology & Life Sciences industry group
57.62%
- AMGN
- 57.62%
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
Dividend Metrics
| Metric | ALNY | AMGN |
|---|---|---|
| Dividend Yield (TTM) | 0.00% | 2.16% |
| Dividend Payout Ratio (TTM) | 0.00% | 57.62% |
Valuation
P/E Ratio (TTM)
Alnylam Pharmaceuticals (ALNY) at 7.88 sits in the cheaper P/E ratio quartile, while Amgen (AMGN) at 26.69 is closer to its industry’s usual earnings multiple — a discount for ALNY, though growth and earnings durability still matter.
ALNY
Pharmaceuticals, Biotechnology & Life Sciences industry group
7.88
- Max
- 85.34
- Q3
- 43.46
- Median
- 26.69
- Q1
- 13.30
- ALNY
- 7.88
- Min
- 0.07
AMGN
Pharmaceuticals, Biotechnology & Life Sciences industry group
26.69
- Max
- 85.34
- Q3
- 43.46
- AMGN
- 26.69
- Median
- 26.69
- Q1
- 13.30
- Min
- 0.07
P/S Ratio (TTM)
On P/S ratio, both Alnylam Pharmaceuticals (ALNY) at 4.17 and Amgen (AMGN) at 6.40 are priced roughly in line with their industries — neither looks cheap nor rich on a sales basis.
ALNY
Pharmaceuticals, Biotechnology & Life Sciences industry group
4.17
- Max
- 58.18
- Q3
- 25.77
- Median
- 7.30
- ALNY
- 4.17
- Q1
- 3.01
- Min
- 0.01
AMGN
Pharmaceuticals, Biotechnology & Life Sciences industry group
6.40
- Max
- 58.18
- Q3
- 25.77
- Median
- 7.30
- AMGN
- 6.40
- Q1
- 3.01
- Min
- 0.01
P/B Ratio (MRQ)
Alnylam Pharmaceuticals (ALNY) at 5.79 sits near its industry’s typical P/B ratio, while Amgen (AMGN) at 17.35 prices above its benchmark range — AMGN looks rich relative to book.
ALNY
Pharmaceuticals, Biotechnology & Life Sciences industry group
5.79
- Max
- 13.53
- Q3
- 6.54
- ALNY
- 5.79
- Median
- 3.25
- Q1
- 1.69
- Min
- -5.59
AMGN
Pharmaceuticals, Biotechnology & Life Sciences industry group
17.35
- AMGN
- 17.35
- Max
- 13.53
- Q3
- 6.54
- Median
- 3.25
- Q1
- 1.69
- Min
- -5.59
Valuation Metrics
| Metric | ALNY | AMGN |
|---|---|---|
| P/E Ratio (TTM) | 7.88 | 26.69 |
| P/S Ratio (TTM) | 4.17 | 6.40 |
| P/B Ratio (MRQ) | 5.79 | 17.35 |
| Free Cash Flow Yield (TTM) | 1.57% | 2.96% |